Lornoxicam | Chlortenoxicam | COX Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / Lornoxicam/氯诺昔康

Lornoxicam/氯诺昔康 {[allProObj[0].p_purity_real_show]}

货号：A152949 同义名： Chlortenoxicam; Ro 13-9297

Lornoxicam是一种非甾体抗炎药（NSAID），其 COX-1 和 COX-2 抑制作用分别具有 IC50 值为 5 nM 和 8 nM，广泛用于缓解各种类型的疼痛。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Lornoxicam/氯诺昔康化学结构
CAS号：70374-39-9

Lornoxicam/氯诺昔康 3D分子结构
CAS号：70374-39-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Lornoxicam/氯诺昔康纯度/质量文件产品仅供科研

货号：A152949 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

环氧化酶亚型比较

产品名称	COX ↓ ↑	COX-1 ↓ ↑	COX-2 ↓ ↑	纯度
Piroxicam	✔			98%
Salicylic acid	✔			98%
Phenacetin	✔			98%
Etodolac	✔			99%
Flunixin meglumine	✔			98%
Ibuprofen L-lysine	✔			98%
Nabumetone	✔			98%
Acemetacin	✔			98%
Diflunisal	✔			98%
Pranoprofen	✔			98%
Ampiroxicam	✔			98%
Meloxicam	✔			98%
Sulindac	✔			98%
Ketoprofen		✔		98%
Mefenamic Acid		✔		95%
Bromfenac sodium		✔		98%
Oxaprozin		✔		99%
Aspirin		✔		99%
Nepafenac		✔		98%
Zaltoprofen		✔		99%
Salicin		✔		98%
Suprofen		✔		99%+
Xanthohumol		✔		99%
Parecoxib			✔	98%
Tolfenamic Acid			+++ COX-2, IC50: 0.2 μM	98%
Etoricoxib			✔	99%
Niflumic Acid			✔	98%
Valdecoxib			++++ COX-2, IC50: 5 nM	99+%
Ibuprofen		+ COX-1, IC50: 13 μM	+ COX-2, IC50: 370 μM	98%
Indomethacin		++ COX1, IC50: 0.28 μM	+ COX-2, IC50: 14 μM	97%
Lornoxicam		++++ COX-1, IC50: 5 nM	++++ COX-2, IC50: 8 nM	98%
Meclofenamic acid sodium		++++ COX-1, IC50: 40 nM	+++ COX-2, IC50: 50 nM	99%
Asaraldehyde			✔	98%
Naproxen		+ COX-1, IC50: 8.7 μM	+ COX-2, IC50: 5.2 μM	98%
Diclofenac Sodium Salt		+++ COX-1, IC50: 60 nM	+++ COX-2, IC50: 200 nM	98%
NS-398			++ COX-2, IC50: 3.8 μM	95%
Amfenac Sodium Hydrate		++ COX-1, IC50: 250 nM	+++ COX-2, IC50: 150 nM	98%+
Nimesulide			+ COX-2, IC50: 26 μM	98%
Lumiracoxib		++ COX-1, Ki: 3 μM	+++ COX-2, Ki: 60 nM	98%
Rutaecarpine			✔	95%
Celecoxib			++++ COX-2, IC50: 40 nM	98%
Carprofen			++++ canine COX2, IC50: 30 nM	98%
Ketorolac		++ COX-1 (human), IC50: 1.23 μM	++ COX-2 (human), IC50: 3.50 μM	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Lornoxicam/氯诺昔康生物活性

靶点

COX-2

COX-2, IC50:8 nM
COX-1

COX-1, IC50:5 nM

描述

Lornoxicam is a strong analgesic and anti-inflammatory NSAID with balanced cyclo-oxygenase (COX-1/COX-2) inhibition and excellent tolerability. Lornoxicam and rofecoxib are effective in the treatment of patients with activated osteoarthritis; the analgesic and anti-inflammatory effects of lornoxicam are significantly superior to those of rofecoxib without inferiority in tolerability^[3]. The developed proniosomal gel (F19) improved the clinical efficacy of lornoxicam as compared to oral therapy. Graphical Abstract Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats^[4]. Lornoxicam was also as effective as other NSAIDs in relieving symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute sciatica and low back pain^[5].

Lornoxicam/氯诺昔康临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01638962	Osteoarthritis, Knee	Not Applicable	Completed	-	Denmark ... 展开 >> University of Southern Denmark Odense, Region Syddanmark, Denmark, 5230 收起 <<
NCT02698995	Postoperative Pain	Phase 3	Unknown	July 2017	Romania ... 展开 >> Foisor Orthopedic Clinical Hospital Recruiting Bucharest, Romania, 021383 Contact: Ana Maria Munteanu, MD PhD 0040722514156 ammunteanu@gmail.com Contact: Denisa Anastase, MD PhD 0040721255339 danastase1@gmail.com Sub-Investigator: Simona Florescu Cionac, MD PhD Sub-Investigator: Ioan Cristian Stoica, MD Prof 收起 <<
NCT01480752	Post Operative Endodontic Pain	Phase 2	Completed	-	Iran, Islamic Republic of ... 展开 >> Dental School of Azad University Tehran, Iran, Islamic Republic of, 1946853314 收起 <<

Lornoxicam/氯诺昔康参考文献

[1]Futaki N, Harada M, et al. The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. J Pharm Pharmacol. 2009 May;61(5):607-14.

[2]Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57.

[3]Rose P, Steinhauser C. Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36

[4]Shah H, Nair AB, Shah J, Bharadia P, Al-Dhubiab BE. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats. Daru. 2019 Jun;27(1):59-70

[5]Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57

Lornoxicam/氯诺昔康实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.45mL

2.69mL

1.34mL

26.89mL

5.38mL

2.69mL

Lornoxicam/氯诺昔康技术信息

CAS号	70374-39-9
分子式	C₁₃H₁₀ClN₃O₄S₂
分子量	371.82
SMILES Code	O=C(C1=C(O)C2=C(C=C(Cl)S2)S(N1C)(=O)=O)NC3=NC=CC=C3
MDL No.	MFCD00866163

别名	Chlortenoxicam; Ro 13-9297; TS 110; Xefocam; Lornoxicamum; Xefo
运输	蓝冰
InChI Key	WLHQHAUOOXYABV-UHFFFAOYSA-N
Pubchem ID	54690031

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 3 mg/mL(8.07 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01638962	Osteoarthritis, Knee	Not Applicable	Completed	-	Denmark ... 展开 >> University of Southern Denmark Odense, Region Syddanmark, Denmark, 5230 收起 <<
NCT02698995	Postoperative Pain	Phase 3	Unknown	July 2017	Romania ... 展开 >> Foisor Orthopedic Clinical Hospital Recruiting Bucharest, Romania, 021383 Contact: Ana Maria Munteanu, MD PhD 0040722514156 ammunteanu@gmail.com Contact: Denisa Anastase, MD PhD 0040721255339 danastase1@gmail.com Sub-Investigator: Simona Florescu Cionac, MD PhD Sub-Investigator: Ioan Cristian Stoica, MD Prof 收起 <<
NCT01480752	Post Operative Endodontic Pain	Phase 2	Completed	-	Iran, Islamic Republic of ... 展开 >> Dental School of Azad University Tehran, Iran, Islamic Republic of, 1946853314 收起 <<
NCT02025166	Pain	Not Applicable	Unknown	January 2015	Israel ... 展开 >> Rambam Health Care Campus Not yet recruiting Haifa, Israel Contact: Lior Lowenstein, MD, MS 972502061434 l_lior@rambam.health.gov.il Principal Investigator: Susana Mustafa, MD 收起 <<
NCT03092193	Poor Metabolizer Due to Cytoch... 展开 >>rome P450 CYP2C9 Variant Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant 收起 <<	Phase 4	Recruiting	December 2018	Brazil ... 展开 >> Bauru School of Dentistry/USP Recruiting Bauru, São Paulo, Brazil, 17012-901 Contact: Adriana M Calvo, PhD 551432358276 birinjela@yahoo.com.br 收起 <<
NCT00293631	Bunionectomy ... 展开 >>Orthopedic Surgery 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Advanced Clinical Research Institute Anaheim, California, United States, 92801 收起 <<
NCT00293657	Headache (Migraine)	Phase 2	Completed	-	-
NCT01564680	Postoperative Pain	Phase 4	Completed	-	Saudi Arabia ... 展开 >> Dammam University, KFHU Al-Khobar, EP, Saudi Arabia, 31952 收起 <<
NCT01069055	Inguinal Hernia ... 展开 >> Postoperative Pain 收起 <<	Phase 3	Unknown	June 2010	Turkey ... 展开 >> Diskapi Teaching and Research Hospital Not yet recruiting Ankara, Turkey Contact: Alp Alptekin, MD +90 312 5962370 alptekinmd@yahoo.com Contact: Hakan Kulacoglu, MD, FACS hakankulacoglu@hotmail.com 收起 <<
NCT02749162	Postoperative Pain	Phase 3	Completed	-	Romania ... 展开 >> Foisor Orthopedics Clinical Hospital Bucharest, Romania, 021382 收起 <<
NCT01718756	Closed Non Comminuted Long Bon... 展开 >>e Fractures 收起 <<	Phase 1 Phase 2	Unknown	February 2016	Egypt ... 展开 >> Anesthesiology Dept., College of Medicine, Mansoura University Recruiting Mansoura, DK, Egypt, 050 Sub-Investigator: Salwa Hawas, MD Principal Investigator: Eiad A Ramzy, MD Sub-Investigator: Douaa G Diab, MD Sub-Investigator: Nahla S El Bahnsawy, MD Sub-Investigator: Hany A Mowafi, MD Sub-Investigator: Talal A Albrahimi, MD 收起 <<
NCT01055470	Osteoarthritis of Knee Joint	Not Applicable	Completed	-	India ... 展开 >> Sir Takthasinhji General Hospital Bhavnagar, Gujarat, India, 364001 收起 <<
NCT01117948	Alzheimer´s Disease	Phase 2	Terminated(Lack of Efficacy)	-	-
NCT01117948	-		Terminated(Lack of Efficacy)	-	-
NCT00997750	Acute Coronary Syndrome	Phase 4	Completed	-	Russian Federation ... 展开 >> Central Clinical Hospital of Presidential Department Of Russian Federation Moscow, Russian Federation 收起 <<
NCT03038321	Non-Muscle-invasive Bladder Ca... 展开 >>ncer (NMIBC) Bacillus Calmette-Guerin (BCG) Cystitis Intra-vesical Instillation 收起 <<	Phase 4	Active, not recruiting	December 2019	Egypt ... 展开 >> Urology and Nephrology Center Mansoura, Aldakahlia, Egypt, 35516 收起 <<
NCT02750917	Postoperative Pain	Phase 3	Completed	-	-

Lornoxicam/氯诺昔康 {[allProObj[0].p_purity_real_show]}

Lornoxicam/氯诺昔康纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Lornoxicam/氯诺昔康质控信息

Lornoxicam/氯诺昔康生物活性

Lornoxicam/氯诺昔康临床研究

Lornoxicam/氯诺昔康参考文献

Lornoxicam/氯诺昔康实验方案

Lornoxicam/氯诺昔康技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Lornoxicam/氯诺昔康 {[allProObj[0].p_purity_real_show]}

Lornoxicam/氯诺昔康 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Lornoxicam/氯诺昔康 质控信息

Lornoxicam/氯诺昔康 生物活性

Lornoxicam/氯诺昔康 临床研究

Lornoxicam/氯诺昔康 参考文献

Lornoxicam/氯诺昔康 实验方案

Lornoxicam/氯诺昔康 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Lornoxicam/氯诺昔康纯度/质量文件产品仅供科研

Lornoxicam/氯诺昔康质控信息

Lornoxicam/氯诺昔康生物活性

Lornoxicam/氯诺昔康临床研究

Lornoxicam/氯诺昔康参考文献

Lornoxicam/氯诺昔康实验方案

Lornoxicam/氯诺昔康技术信息